Literature DB >> 6099986

The role of second-look procedures in the management of retroperitoneal tumors in children.

J L Grosfeld, K W West, T R Weber.   

Abstract

Forty-two infants and children with retroperitoneal solid tumors underwent second operative procedures. Twenty-three children had stage III (4) or stage IV (19) neuroblastoma and 19 had Wilms' tumor. This report suggests that second-look procedures are quite beneficial in selected cases. In children with Wilms' tumor, second procedures are most useful in those patients inadequately staged with flank operations, in cases of bilateral tumors, and in children with initially unresectable tumors following cytoreduction. Patients with significant tumor spill at a previous procedure may also benefit from early reoperation. Late recurrence of tumor, especially in children with unfavorable histology and/or hematogenous liver metastases, carries an ominous prognosis. Ten of the 19 patients with Wilms' tumor are long-term survivors (52.6%). Patients with initially unresectable (stage III) neuroblastoma occurring in the pelvis respond well to second-look resection. Children with primary tumors surrounding the celiac axis eventually died despite subsequent resection. Although the efficacy of primary tumor resection in cases of metastatic neuroblastoma remains controversial, stage IV patients with tumor resection had a longer duration of survival. Our only long-term survivors had their primary tumors resected. Second-look or delayed abdominal operations in metastatic cases may be useful in assessing the effectiveness of treatment and for sampling of retroperitoneal lymph nodes as a prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6099986     DOI: 10.1097/00043426-198424000-00009

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  1 in total

1.  Neuroblastoma arising from the celiac ganglion.

Authors:  F Ito; T Ito; H Ando; T Seo
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.